Overview
Home   Overview   Programme/Posters   Speakers/Abstracts   Presentations   Sponsors   Symposium Pictures   Symposium Report   Kinase Links   Meetings   Speakers Articles		The meeting is partially prompted by the fact that 2006 will see the 20th anniversary of the start of tyrosine kinase inhibitor research in Basel. This event ultimately led to the development of the first protein kinase therapeutic, Glivec. The symposium will focus on the impact of basic research on drug discovery and the impact that it is now having on treatment of cancer. We also wish to focus on contemporary issues in the protein kinase field, surveying the current landscape in terms of the development of targeted kinase inhibitors for cancer, and other areas. We hope to bring together basic researchers, chemists, pharmacologists, clinicians and the major contributors from the pharma industry. We look forward very much to your participation. Organizers: - Dr Brian A. Hemmings, FMI, Basel - Prof. Paul Herrling, Corporate Research, Novartis, Basel - Dr. Myoung-Ok Kwon, Corporate Research, Novartis, Basel Scientific committee: - Prof. Max M. Burger, Novartis Science Board, Basel - Dr Brian A. Hemmings, FMI, Basel - Prof. Paul Herrling, Corporate Research, Novartis, Basel - Prof. Bill Sellers, NIBR, Boston Conference logistics : Isabella Bogdal, Phone: +41-61-6976653 Fax: +41-61-6973976 isabella.bogdal@fmi.ch Thibaut Siegmann, Phone: +41-61-6975187 Fax: +41-61-6973976 thibaut.siegmann@fmi.ch Nadine Streich, Phone: +41 61 324 6009 Fax: +41 61 324 2522 nadine.streich@novartis.com Sponsors: - Prof. Mark Fishman, President of the Novartis Institutes for BioMedical Research, Boston - Prof. Susan Gasser, Director of the Friedrich Miescher Institute for Medical Research, Basel - Prof. Paul Herrling, Head of Corporate Research, Novartis, Basel © Basel Tourismus + Stadtmarketing Basel, www.basel.ch